Go Pro
NASDAQ:SION

Sionna Therapeutics Q2 2025 Earnings Report

Sionna Therapeutics logo
$5.51 -0.51 (-8.47%)
Closing price 04:00 PM Eastern
Extended Trading
$5.49 -0.02 (-0.29%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sionna Therapeutics EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.68
Beat/Miss
Beat by +$0.27
One Year Ago EPS
N/A

Sionna Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sionna Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 11, 2025
Conference Call Time
7:00AM ET

Sionna Therapeutics Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Sionna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sionna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sionna Therapeutics and other key companies, straight to your email.

About Sionna Therapeutics

Sionna Therapeutics (NASDAQ:SION) is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disease that affects the lungs and other organs. The company is developing small-molecule therapies designed to address defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is responsible for transporting salt and fluids across cell membranes.

Sionna’s research is centered on nucleotide-binding domain 1 (NBD1) correctors. These investigational medicines are intended to stabilize and improve the function of defective CFTR proteins, including proteins affected by the common F508del mutation. The company’s approach is designed to potentially form part of combination therapies that target multiple stages of CFTR production, processing and activity.

Sionna’s pipeline includes preclinical and clinical-stage programs evaluating the safety, tolerability and pharmacological activity of its CFTR modulators. The company’s goal is to develop oral treatments that may benefit a broad population of people with cystic fibrosis, including patients who have limited treatment options because of the specific mutations they carry.

View Sionna Therapeutics Profile